Evidence map›Paper›PMID 36896611›Full record

ArticleEMBO reports2023

SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth.

Jing Jin, Lin Bai, Dongyao Wang, Wei Ding, Zhuoxian Cao, Peidong Yan, Yunjia Li, Lulu Xi, Yuxin Wang, Xiaohu Zheng and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
190citing papers in PubMed, 1 pooled it
34.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

190 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Unveiling Lactylation: A Novel Frontier in Cancer Stemness and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

130 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jing Jin *Division of Life Sciences and Medicine, Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Heifei, China.ORCID 0000-0003-3232-4141
Lin Bai *State Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Human Phenome Institute, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-8892-8249
Dongyao Wang *Division of Life Sciences and Medicine, Department of Hematology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.ORCID 0000-0003-1720-1135
Wei DingBeijing National Laboratory for Condensed Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing, China.
Zhuoxian CaoDivision of Life Sciences and Medicine, Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Heifei, China.
Peidong YanDivision of Life Sciences and Medicine, Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Heifei, China.ORCID 0000-0001-7621-7239
Yunjia LiDivision of Life Sciences and Medicine, Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Heifei, China.
Lulu XiDivision of Life Sciences and Medicine, Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Heifei, China.
Yuxin WangDivision of Life Sciences and Medicine, Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Heifei, China.
Xiaohu ZhengInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, China.
Haiming WeiInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, China.ORCID 0000-0002-1675-6502
Chen DingState Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Human Phenome Institute, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-8673-3464
Yi WangDivision of Life Sciences and Medicine, Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Heifei, China.ORCID 0000-0003-0797-5209
University of Science and Technology of China · CNChinese Academy of Sciences · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysine lactylation (Kla) is a recently discovered histone mark derived from metabolic lactate. The NAD

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsSirtuin 3Cell ProliferationCyclinsHumansLysineCyclinsLysineSIRT3 protein, humanSirtuin 3CCNE2hepatocellular carcinomaHonokiollactylationSIRT3

Identifiers

PMID36896611
PMCPMC10157311
OpenAlexW4323809566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.